ES2502366T3 - Inducción de inmunidad tumoral por variantes de proteína de unión a folato - Google Patents

Inducción de inmunidad tumoral por variantes de proteína de unión a folato Download PDF

Info

Publication number
ES2502366T3
ES2502366T3 ES11004714.9T ES11004714T ES2502366T3 ES 2502366 T3 ES2502366 T3 ES 2502366T3 ES 11004714 T ES11004714 T ES 11004714T ES 2502366 T3 ES2502366 T3 ES 2502366T3
Authority
ES
Spain
Prior art keywords
binding protein
folate
induction
tumor immunity
protein variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES11004714.9T
Other languages
English (en)
Inventor
Constantin G. Ioannides
George E. Peoples
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
University of Texas at Austin
Original Assignee
University of Texas System
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Henry M Jackson Foundation for Advancedment of Military Medicine Inc, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2502366T3 publication Critical patent/ES2502366T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un antígeno que comprende un epítope de proteína de unión a folato de SEC ID Nº: 2, SEC ID Nº: 3, SEC ID Nº: 4, SEC ID Nº: 5, SEC ID Nº: 6, SEC ID Nº: 7, SEC ID Nº: 8, o una combinación de las mismas.

Description

Inducción de inmunidad tumoral por variantes de proteína de unión a folato
DESCRIPCIÓN
A
ES11004714.9T 2001-03-09 2002-03-08 Inducción de inmunidad tumoral por variantes de proteína de unión a folato Expired - Lifetime ES2502366T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27467601P 2001-03-09 2001-03-09
US274676P 2001-03-09

Publications (1)

Publication Number Publication Date
ES2502366T3 true ES2502366T3 (es) 2014-10-03

Family

ID=23049174

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11004714.9T Expired - Lifetime ES2502366T3 (es) 2001-03-09 2002-03-08 Inducción de inmunidad tumoral por variantes de proteína de unión a folato

Country Status (9)

Country Link
US (5) US7547759B2 (es)
EP (2) EP1472337A4 (es)
JP (3) JP4401075B2 (es)
CA (1) CA2440610C (es)
DK (1) DK2371854T3 (es)
ES (1) ES2502366T3 (es)
PT (1) PT2371854E (es)
SI (1) SI2371854T1 (es)
WO (1) WO2002072766A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1472337A4 (en) * 2001-03-09 2008-02-27 Univ Texas INDUCTION OF TUMORIMMUNITY BY VARIATIONS OF THE FOLAT BINDING PROTEIN
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
WO2007008488A2 (en) * 2005-07-06 2007-01-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Stable quantitation and detection of immune response levels with non-zero background peptides
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
MA45169A (fr) 2016-05-31 2019-04-10 Sellas Life Sciences Group Inc Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
EP3290395A1 (en) * 2016-09-02 2018-03-07 Paques I.P. B.V. Anaerobic purification device with variable water column
CN118634339B (zh) * 2017-02-17 2025-07-01 珀杜研究基金会 用于细胞疗法的基于靶向性配体-有效负载的药物递送
SG11202100616VA (en) 2018-08-07 2021-03-30 Purdue Research Foundation Rejuvenation of car t cell

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826364A (en) 1972-05-22 1974-07-30 Univ Leland Stanford Junior Particle sorting method and apparatus
US4284412A (en) 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4498766A (en) 1982-03-25 1985-02-12 Becton, Dickinson And Company Light beam focal spot elongation in flow cytometry devices
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
JP2000505787A (ja) * 1996-01-05 2000-05-16 アメリカ合衆国 中皮抗原及びそれを標的化するための方法及びキット
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2002065992A2 (en) * 2001-02-20 2002-08-29 Ortho-Mcneil Pharmaceutical, Inc. A cell therapy method for the treatment of tumors
EP1472337A4 (en) * 2001-03-09 2008-02-27 Univ Texas INDUCTION OF TUMORIMMUNITY BY VARIATIONS OF THE FOLAT BINDING PROTEIN
US9993538B2 (en) * 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors

Also Published As

Publication number Publication date
JP2004532825A (ja) 2004-10-28
US8258261B2 (en) 2012-09-04
CA2440610A1 (en) 2002-09-19
US20150175658A1 (en) 2015-06-25
US7547759B2 (en) 2009-06-16
WO2002072766A2 (en) 2002-09-19
EP2371854A2 (en) 2011-10-05
CA2440610C (en) 2011-07-12
JP5017238B2 (ja) 2012-09-05
PT2371854E (pt) 2014-08-25
US8815256B2 (en) 2014-08-26
DK2371854T3 (da) 2014-08-11
US20180194806A1 (en) 2018-07-12
EP1472337A1 (en) 2004-11-03
EP2371854B1 (en) 2014-05-07
JP2009114190A (ja) 2009-05-28
US20130039935A1 (en) 2013-02-14
US20030185840A1 (en) 2003-10-02
JP2012097111A (ja) 2012-05-24
EP1472337A4 (en) 2008-02-27
WO2002072766A8 (en) 2004-09-02
EP2371854A3 (en) 2011-12-21
JP4401075B2 (ja) 2010-01-20
US9562070B2 (en) 2017-02-07
US20090227510A1 (en) 2009-09-10
SI2371854T1 (sl) 2014-09-30

Similar Documents

Publication Publication Date Title
ATE542829T1 (de) Impfstoff
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
EP1280540A4 (en) MODIFIED FACTOR VIII
PT1557462E (pt) Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
WO2004030608A3 (en) Nanoemulsion vaccines
GB0014907D0 (en) Antigenic polypeptides
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE363531T1 (de) Claudin polypeptide
EP1462456A4 (en) TUMOR ANTIGENS
MXPA04005079A (es) Variantes del dominio c2 del factor viii.
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
EP2371854A3 (en) Induction of tumor immunity by variants of folate binding protein
ATE305796T1 (de) Präparationen von vitamin e in kombination mit afamin
BR0111785A (pt) Composições e métodos para tratamento de candidìase
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
WO2002038803A3 (de) Neue marker für die diagnose und therapie von tumoren